Zeng Qingchun, Cheng Zhendong, Xia Yi, Cheng Rui, Ou Ailian, Li Xinrui, Xu Xingbo, Huang Yuli, Xu Dingli
State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou , China.
State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Ther Adv Chronic Dis. 2020 Oct 14;11:2040622320949068. doi: 10.1177/2040622320949068. eCollection 2020.
Atrial fibrillation (AF) is prevalent in patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). Depending on the timing of AF detection, it is usually categorized as pre-existing AF or new-onset AF. Antiplatelet therapy, rather than a vitamin K antagonist, may be considered as the primary treatment for patients without an indication for oral anticoagulants who undergo TAVR. However, the optimal postprocedural antithrombotic regimen for patients with AF undergoing TAVR remains unknown. In this review, we briefly introduce the management strategies of antithrombotic therapy and list the evidence from related studies to elucidate the optimal antithrombotic management for patients with AF undergoing TAVR.
心房颤动（AF）在接受经导管主动脉瓣置换术（TAVR）的主动脉瓣狭窄（AS）患者中很常见。根据房颤检测的时间，通常将其分为既往存在的房颤或新发房颤。对于未接受口服抗凝剂治疗且接受TAVR的患者，抗血小板治疗而非维生素K拮抗剂可被视为主要治疗方法。然而，接受TAVR的房颤患者术后最佳抗栓方案仍不清楚。在本综述中，我们简要介绍抗栓治疗的管理策略，并列出相关研究的证据，以阐明接受TAVR的房颤患者的最佳抗栓管理。
